drugset / Trial / NCT07705737
Rademikibart IV for Acute Asthma and COPD Exacerbation
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Timeline
- Start
- 2026-07-30
- Primary completion
- 2026-12
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rademikibart | Monoclonal antibody | 300 mg | Intravenous |